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Cardiovascular Topics 
Effect of magnesium on myocardial 
ischaemia and reperfusion injury 
STEFAN MALHERBE, SUZANNE CONRADIE, ANDRE COETZEE 
Summary 
This study examined the effect of intravenous magne-
sium on the reperfusion injury of the porcine 
myocardium. Animals received general anaesthesia and 
the left anterior descending coronary artery was 
occluded for 15 minutes. Thereafter, reperfusion was 
allowed for 60 minutes. Regional ventricular function 
was measured with microsonometers. Animals were ran-
domly assigned to a control (N = 6) or a magnesium 
group (N = 6). The latter received 30 mglkg magnesium 
immediately before the release of the occlusion on the 
left anterior descending (LAD) artery. 
Results indicate that magnesium administration is 
associated with fewer ventricular arrhythmias and a 
rapid recovery (within 5 minutes) of myocardium sys-
tolic function once reperfusion was initiated. In the con-
trol group myocardial stunning was prolonged and more 
reperfusion arrhythmias occurred. However, in the 
group that received magnesium there was more diastolic 
dysfunction during reperfusion. 
S Afr Med J 1999; 89: Cardiovascular suppl3, C135-C140. 
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Myocardial reperfusion injury consists of arrhythmias, 
accelerated cell death and prolonged reversible post-ischaemic 
dysfunction (stunning).! A number of possible explanations 
have been proposed, but the generation of free oxygen radicals, 
leading to intracellular calcium overload and prolonged dys-
function, is currently a popular explanation for reperfusion 
injury?·5 This conclusion is further confIrmed by data which 
demonstrate that the modulation of intracellular calcium over-
load early in the reperfusion period decreases myocardial stun-
ning.6-8 
Magnesium has been termed nature's physiological calcium 
blocker.9 Excess magnesium blocks and a defIciency of magne-
sium accentuates the actions of calcium. This has led to various 
studies that have examined the effect of magnesium on experi-
mental myocardial ischaemia and infarction,IQ.JJ as well as to 
clinical trials that have examined the hypothesis that magne-
sium may be benefIcial to the patient who has had a myocardial 
infarction."·17 
Two experimental studies examined the effects of 
magnesium on regional myocardial performance during stun-
ning.'8.19 They demonstrated that magnesium supplementation 
improved, and magnesium depletion aggravated, stunning. 
However, both studies were performed under isoflurane anaes-
thesia, while previous studies suggest that isoflurane improves 
myocardial stunning?o.21 In addition, these studies did not 
address the effect of magnesium on reperfusion arrhythmias. 
The aim of this study, therefore, was to evaluate the effect of 
magnesium administered immediately before the initiation of 
reperfusion on myocardial reperfusion injury, with emphasis on 
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Methods 
This study was conducted with the permission of the Ethics 
Committee of the University of Stellenbosch Medical 
School and animals were cared for in accordance with insti-
tutional and international guidelines. 
Twelve pigs were premedicated with intramuscular 
ketamine (5 mg/kg). An intravenous infusion of 0.9% NaCI 
was started in an ear vein and anaesthesia was induced with 
pentobarbital (8 mg/kg; Entha-naze, Centaur, SA) and 
lorazepam (1 mg) administered intravenously. With loss of 
the eyelid reflex, a tracheotomy was performed, the trachea 
was intubated, and the animals were ventilated with 50% 
oxygen and nitrogen. The tidal volume was set at 15 ml/kg 
and the rate adjusted to maintain the end-expired PC02 at 35 
mmHg. Anaesthesia was maintained with a constant infu-
sion of pentobarbital (3 mg/kg/h) and fentanyl (Tanyl; 
Intramed, SA), given initially as a bolus of 20 pg/kg and 
then followed by a constant infusion of 10 pg/kg/h. Muscle 
relaxation was achieved with vecuronium (Norcuron; 
Omnimed, SA), initially administered as a bolus of 0.2 
mg/kg followed by a constant infusion of 0.3 mg/kg/h. 
Temperature of the animals was maintained between 
36.5 and 37.5°C using an under-table heating device, and 
0.9% NaCl (13 ml/kg/h) was used as maintenance intra-
venous fluid. 
A neck dissection was performed and a stiff cannula 
inserted into the proximal aorta via the internal carotid 
artery. This was connected to a transducer (Medex; Medex 
Med Inc., UK) and was used to measure aortic systolic, dia-
stolic and mean arterial (MAP) pressures continuously. The 
latter was obtained from the area under the aortic pressure 
recording. A pulmonary artery catheter (7F; Arrow, USA) 
was inserted for the determination of cardiac output (CO) by 
thermodilution (Edwards; Baxter, USA). This was calcu-
lated after injection of 5 ml 5% dextrose over approximately 
4 seconds into the proximal port. The average of three val-
ues was used for subsequent calculations. 
One femoral artery was exposed and a Fogarty occlusion 
catheter (Fogarty; Baxter, USA) was inserted with the bal-
loon lying above the diaphragm but distal to the left subcla-
vian artery. By inflating the balloon, left ventricular (LV) 
afterload was raised to allow for the recording of afterloaded 
beats. 
A sternotomy and pericardectomy were performed. A 
1 cm length of the left anterior descending (LAD) coronary 
artery distal to the first diagonal branch was mobilised from 
the underlying muscle and a silk loop was placed around the 
artery. This was used to occlude the LAD during the proto-
col. 
A stiff 16-gauge cannula was inserted into the LV cavity 
through an apical stab incision and connected to a trans-
ducer (Medex, UK) for continuous recording of LV systolic, 
diastolic and end-systolic pressures (Pes). Pes was taken at 
the time the aortic valve closed (as judged from the dicrotic 
notch on the aortic pressure recording). 
Two pairs of microsonometers were inserted into the LV 
subendocardium, one pair in the region supplied by the 
LAD artery (distal to the proposed occlusion) and the sec-
ond in the region supplied by the circumflex coronary artery 
(LX), which was used as control during the interventions. 
Signals were transduced (Schuessler and Ass., USA) and 
maximum segment length (Lmax) at the end of diastole, as 
well as minimum segment length at the end of systole 
(Lmin), were recorded. The difference between Lmax and 
Lmin reflected regional segmental shortening (dL). 
Shortening that occurred after the aortic valve closure was 
termed post-systolic shortening (PSS), and was expressed as 
a percentage of the total regional shortening (PSS%). This 
was an indication of early (isovolaemic) diastolic dysfunc-
tion. 
LV pressure and regional length signals were combined 
to give beat-by-beat pressure-length loops. By raising the 
afterload with the aortic balloon, various pressure-length 
loops were recorded. The computer recognised the end-sys-
tolic pressure-length points of the various loops and per-
formed a linear regression on these points. The slope of this 
was termed the end-systolic pressure-length relationship or 
end-systolic elastance (Ees), and was used as an index of 
regional myocardial contractility.22.23 The intercept of this 
regression on the length axis (x-axis) is the extrapolated 
regional segment length when the pressure is zero. This is 
the unstressed LV volume (Lo). 
The product of the Pes and dL, i.e. the area under the 
pressure-length loop (excluding the post-systolic shorten-
ing), is an index of regional stroke work (RSW). 
Before the occlusion of the LAD (see below), 1 mg/kg 
heparin (Heparin; Intramed, SA) was given intravenously to 
prevent clot formation in the LAD artery during the period 
of occlusion. 
All the transduced signals were digitised at a sampling 
rate of 100 Hz by computer, running a custom-made pro-
gramme (A LAB , written by Ralph Pinna, Paul Baily and 
lohan Coetzee, SED and Department of Anaesthesiology, 
University of Stellenbosch). Data were recorded for 30 sec-
onds at zero airway pressure and later redisplayed to evalu-
ate the quality of the measurements. 
Statistical analyses included analysis of variance 
(ANOV A) and the multiple-range test to define homoge-
neous groups. Proportions were analysed with the chi-
squared test, and regression utilised the method of least 
squares. A probability of P = 0.05 was accepted as indica-
tive of a significant difference between values. 
Protocol 
After completion of surgery, a 20-minute stabilisation 
period was allowed. Controlled measurements were made 
(CONTROLS), and thereafter the LAD artery was totally 
occluded for 15 minutes. Twelve minutes into the occlusion, 
data were recorded (ISCHAEMIA), whereafter the occlu-
sion was released at 15 minutes. At 5 minutes (REPERFU-
SION + 5), 30 minutes (REPERFUSION + 30) and 60 min-
utes (REPERFUSION + 60), data were again recorded. 
Animals were randomly assigned to two groups. One 
group received no treatment before reperfusion (control 
group), and the other group received 30 mg/kg magnesium 
sulphate intravenously 2 minutes before reperfusion of the 
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TABLE I. GENERAL HAEMODYNAMICS (MEAN ± SD) 
HR MAP LVEDP CO SV SW +dp/dt -dp/dt Pes 
(beats/min) (mmHg) (mmHg) (l/min) (ml) (g/m) (mmHg/sec) (mmHg/sec) (mmHg) 
Control (N = 6) 
Control 117.33 74.00 4.30 3.46 29.67 29.01 1 583.50 -1 430.33 58.83 
± 9.12 ±12.49 ± 2.39 ±0.68 ± 6.17 ± 8.59 ± 251.56 ± 203.44 ±9.86 
Ischaemia 110.33 74.00 11.98' 3.28 29.76 25.60 1549.00 -1450.83 65.88 
±7.34 ±12.71 ±4.51' ±O.42 ±3.34 ±6.20 ±311.80 ±306.80 ±13.63 
Reperfusion 114.17 72.33 8.80 4.00 35.18 30.65 1 386.37 -1 390.00 68.17 
+5 min ± 8.86 ± 14.36 ± 1.54 ± 0.31 ±2.77 ± 5.80 ±175.o6 ± 317.04 ± 10.48 
Reperfusion 109.67 86.83 7.47' 3.18 29.06 31.63 1 615.33 -I 634.50 76.33 
+ 30 min ±7.87 ±7.06 ± 2.88 ±0.47 ±4.64 ±3.04 ± 221.98 ± 326.63 ± 13.21 
Reperfusion 110.67 85.00 6.72 3.42 31.35 33.25 1770.17 1615.83 64.38 
+60min ± 15.87 ± 13.10 ± 1.84 ±0.74 ±7.74 ± 6.71 ± 441.03 ± 220.51 ± 10.88 
Magnesium (N = 6) 
Control 102.00 71.83 5.62 3.45 34.86 32.89 2106.83 -1471.33 63.78 
± 22.15 ± 13.64 ± 1.45 ± 1.02 ± 10.01 ±14.40 ±567.18 ± 417.24 ± 25.28 
Ischaemia 114.50 70.33 10.03' 3.38 29.74 25.67 1 753.67 -1 134.67 65.50 
±8.90 ± 16.52 ±4.79 ±O.74 ± 7.40 ± 11.71 ± 321.25 ± 618.50 ± 6.24 
Reperfusion 103.00 78.33 IUS' 3.20 32.58 29.94 1734.00 -1389.67 65.40 
+5 min ±19.40 ± 22.13 ±2.17 ± 1.11 ±13.84 ± 15.91 ± 429.01 ±470.50 ±23.01 
Reperfusion 107.83 81.33 9.71' 3.42 31.66 31.74 2002.67 -1341.17 72.83 
+ 30 min ± 9.37 ± 14.49 ±3.09 ±0.53 ± 3.33 ± 8.90 ± 503.61 ±371.Q1 ±18.82 
Reperfusion 108.00 93.60 10.82' 3.44 33.23 36.45 2048.50 -1696.50 76.98 
+60 min ± 22.60 ± 17.81 ±4.56 ±0.50 ±7.70 ± 8.20 ± 506.75 ± 545.41 ± 11.58 
HR = heart rate; MAP = mean arterial pressure; LVEDP = LV end-diastolic pressure; CO = cardiac output; SV = stroke volume; SW = stroke work; 
dp/at = rate of isovolaemic pressure increase; -dp/dt = rate of pressure decrease during isovolaemic relaxation; Pes = LV end-systolic pressure. 
Compares designated value to control: 
*P<O.OI. 
Ventricular extrasystolic beats that were multifocal or 
that occurred more than three times in any 30-second 
period, as well as ventricular tachycardia (associated with an 
acceptable perfusion pressure), were treated with lignocaine 
I mg/kg intravenously. This was repeated if necessary. If 
ventricular fibrillation occurred or the ventricular tachycar-
dia did not respond to lignocaine, direct myocardial defibril-
lation was performed using 5, 5, 10, 10, 15 joules (J) in 
sequence. The doses of lignocaine and the total joules were 
recorded. 
Results 
Global myocardial function (Table I) 
Global myocardial function remained stable throughout the 
experiments in both groups. The only variable that did 
change was the left ventricular end-diastolic pressure 
(L VEDP), which increased significantly in both groups dur-
ing the phase of acute LAD occlusion (ISCHAEMIA). 
L VEDP remained elevated up to 30 minutes in the control 
and 60 minutes in the magnesium groups. 
Regional myocardial function (Table II) 
No changes occurred in the region supplied by the circum-
flex coronary artery . 
Occlusion of the LAD artery caused immediate and 
severe regional dysfunction. Systolic shortening in both 
experimental groups decreased significantly. The OIi.ly 
regional shortening that did occur was in diastole (PSS). 
This inappropriate shortening was also reflected in the sig-
nificant decrease in regional stroke work in both groups, 
which occurred during ischaemia. Extrapolated regional 
length at the time LV pressure was zero (Lo) increased sig-
nificantly in the control animals, but the apparent numerical 
increase failed to reach statistical significance in the magne-
sium group. 
During reperfusion regional systolic shortening in the 
magnesium group recovered quickly so that at 5 minutes' 
reperfusion dL was no different from its own control value. 
In the control group, however, regional shortening recov-
ered more slowly and only at 30 minutes' reperfusion was 
the value for dL not significantly different from its control. 
The post-systolic shortening in the control group returned to 
control values at 5 minutes' reperfusion as opposed to the 
magnesium group where PSS only returned to normal val-
ues at 30 minutes' reperfusion. 
In both groups the RSW had improved at 5 minutes' 
reperfusion, which was no different from control at that 
time. 
Reperfusion arrhythmia (Table III) 
The control group required significantly more lignocaine as 
well as more defibrillation than the magnesium group. 
Discussion 
Results from this study demonstrate that: (i) magnesium 
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• 
TABLE II. REGIONAL MYOCARDIAL FUNCTION (MEAN ± SD) 
LAD LX 
Lmax dL Lo Ees PSS RSW max dL dL% Lo Ees PSS RSW 
(mm) (mm) (mm) (mmHg/mm) (%) (mmHg/mm) (mm) (mm) (%) (mm) (mmHg/mm) (%) (mmHg/mm) 
Control (N = 6) 
Control 5.94 1.00 3.51 150.30 0 57.72 5.44 0.38 6.81 4.18 424.30 0 21.66 
±0.89 ±0.34 ±0.93 ± 160.30 ±20.31 ±0.79 ±0.20 ±2.84 ± 159 ±400.80 ±9.02 
Ischaemia 659 0.08* 5.14* 190.33 95.32 1 5.851 5.62 0.38 6.64 5.25 283.13 1.59 25.97 
±0.68 ±0.12 ± 1.32 ± 162.49 ± 25.60 ±9.27 ±0.70 ±0.19 ±2.57 ±0.84 ±178.72 ±3.55 ± 14.87 
Reperfusion 656 054* 5.10* 111.83 17.83 3752 5.47 0.30 5.49 4.61 300.67 0 21.26 
+5 min ±0.86 ±D.10 ±0.45 ±54.99 ± 16.23 ± 10.40 ±0.64 ±0.10 ± 1.35 ±O.61 ±186.79 ±9.69 
Reperfusion 6.70 0.76 3.72 76.17 13.40 57.65 5.63 0.35 6.14 4.85 287.17 0 27.75 
+30min ±0.77 ±0.25 ±0.56 ±57.16 ± 13.31 ±22.74 ±0.63 ±0.10 ± 1.46 ±0.54 ± 126.83 ± 11.75 • Reperfusion 658 0.80 4.02* 67.17 6.90 50.57 5.60 0.36 6.43 4.29 265.33 0 23.18 
+60min ±0.82 ±0.25 ±0.68 ±21.69 ±8.90 ± 1452 ±0.65 ±0.12 ± 1.87 ± 1.30 ± 15153 ±8.38 
Magnesium (N = 6) 
Control 5.88 0.47 4.13 461.17 0 27.09 5.57 0.43 8.03 4.83 325.00 0 24.43 
±0.49 ±0.31 ± 1.98 ± 503.48 ± 18.06 ± 1.33 ±0.14 ±2.84 ± 1.36 ±86.55 ±4.57 
Ischaemia 6.21 0.10* 5.61 253.33 68.90t 8.69* 5.72 0.32 5.24 4.99 281.50 0 20.12 
±0.51 ±0.10 ±051 ±173.04 ±4.78 ±5.78 ±1.44 ±0.18 ± 1.88 ± 1.14 ± 146.17 ± 10.23 
Reperfusion 6.10 0.45 4.89 153.67 30.S8t 27.77 5.33 0.34 6.30 4.72 339.33 0 23.13 
+ 5 min ±0.45 ±0.32 ±0.55 ± 59.84 ±30.29 ± 18.56 ±0.72 ±0.14 ±2.13 ±0.84 ± 226.18 ± 11.62 
Reperfusion 5.92 0.56 4.26 101.67 3.29 40.79 5.31 0.41 7.68 3.51 277.50 0 30.17 
+30min ±D.72 ±D.25 ±O.76 ±47.60 ±5.09 ±19.73 ±D.64 ±D.16 ±2.74 ±1.39 ±169.42 ±15.45 
Reperfusion 5.97 0.65 4.43 94.67 3.56 51.55 5.30 0.40 753 4.54 282.00 0 30.28 
+60 min ±0.73 ±0.34 ± 1.29 ± 61.78 ±7.37 ±29.79 ±0.58 ±D.14 ±2.49 ±0.67 ± 271.59 ± 10.65 
Lmax = maximum regional length; dL = regional systolic shortening; dL % = dllmax x 100; Lo = LV regional length when LV pressure = zero; Ees = end- • 
systolic pressure - volume relation, PSS = post-systolic shortening; RSW = regional stroke work; LAD and LX = areas supplied by LAD and circumflex 
coronary arteries. 
Compares designated value to own control: 
*P.<0.05. 
tP < 0.01. 
:j:P< 0.001. 
fewer ventricular arrhythmias; (ii) systolic function (stun-
ning) recovered more rapidly during reperfusion in animals 
that received magnesium; and (iii) recovery of diastolic 
function during reperfusion occurred more slowly in the 
presence of additional magnesium. 
Magnesium has been termed 'nature's physiological cal-
cium blocker'.9 It probably blocks the slow inward current 
of calcium and stabilises the electrical activity of the sinus 
node and atrial musc1e,24-26 while intracellular magnesium 
inhibits the release of calcium from the sarcoplasmic reticu-
lum (SR) during calcium-induced calcium release.2? Reports 
suggest that magnesiuni drives the calcium into the SR by 
stimulation of the Ca-ATPase enzyme activity,28 and in 
addition also competes with calcium at certain binding sites 
on troponin-C and myosin, thereby decreasing the ability of 
calcium to increase myocardial tension.29 It is therefore not 
unexpected that studies have shown that magnesium 
decreases myocardial contractility and inhibits certain 
arrhythmias.30-35 
Large clinical studies were conducted to evaluate the 
effect of magnesium administered to patients who had 
already suffered a myocardial infarction.14.15,l7 The conclu-
sion of the LIMIT-214 and ISIS-417 studies were, however, 
contradictory inasmuch as the LIMIT-2 trial showed some 
benefit while the ISIS-4 trial failed to confirm beneficial 
effects from magnesium administration. A randomised but 
smaller study also showed beneficial effects when magne-
sium was given to patients who had suffered a myocardial 
infarction.36 Animal studies of infarct size showed less 
extensive infarction if magnesium was administered during 
myocardial ischaemia and the reperfusion period. II -13 
The timing of the magnesium administration seems to be 
important, as was demonstrated by Hertzog et ai. 18 In their 
animal study the late administration of magnesium (1 hour 
after reperfusion was initiated) did not limit reperfusion 
arrthythmias or infarct size. This was in contrast to the bene-
ficial effect obtained from administration of magnesium 
immediately at the onset of reperfusion.12 Data suggest that 
oxygen radical formation peaks at approximately 3 minutes and 
intracellular calcium overload is maximal at approximately 5 
minutes.4~? Whatever antagonist is considered will therefore 
have to be administered during this critical early period of 
reperfusion or be present when reperfusion is initiated. 
This study did not set out to evaluate the effects of mag-
nesium on infarction, but rather to evaluate the effects of 
magnesium as a mechanism to modulate the reperfusion 
injury. Previous studies have addressed this issue but were 
performed under isoflurane anaesthesia. IB •19 Inhalation anaes-
thetics such as isoflurane have their own protective effects 
during reperfusion and could therefore have played a role in 
the results already published.20 .21 
Results from this study can be viewed as support for the 
theory and previously published results that suggest a pro-
tective effect of magnesium during reperfusion. 2o.21 The 
administration of magnesium resulted in less ventricular 
arrhythmias and reduced the requirements for lignocaine 
and defibrillation. This beneficial effect of magnesium is 
probably related to its calcium-blocking effect. Partially 
depolarised myocardial cells (which do not usually initiate 
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TABLE m. ANIMAL WEIGHT, MAGNESIUM BLOOD 
CONCENTRATION, LIGNOCAINE AND DEFIBRILLA-
TION REQUIREMENTS (MEAN ± SD) 
Control (N = 6) Magnesium (N = 6) 
Weight (kg) 27.4 23.93 
±2.65 1.91 
Magnesium (mmolll) 0.76 Before mg2+ 0.79 
±0.05 
± 0.11 After mg2+ 1.671 
±0.15 
Lignocaine (mg) 41.3t 13.4 
± 10.3 ±5.9 
Joules 41.3* 23.8 
± 10.3 ± 8.1 
Compare control with magnesium: 'P < 0.05. tp < 0.001. 
ICompare before with after mg'+: P < 0.0001. 
be blocked by calcium channel blockers or low extracellular 
calcium. Early afterdepolarisation is also induced by par-
tially depolarised cells and this effect is enhanced by cal-
cium overload of cells. Both early afterdepolarisation and 
delayed afterpolarisation can be suppressed by low extracel-
lular calcium concentration or calcium channel blockers. 
Furthermore, calcium channel blockers decrease the ten-
dency towards ventricular fibrillation in ischaemic hearts?4 
Data from rat experiments demonstrated fewer reperfusion 
arrhythmias in the presence of high magnesium and more 
conduction pathology in the presence of low magnesium.38 
Iseri32 discussed the beneficial effects of magnesium on ven-
tricular tachyarrhythmias and concluded that magnesium is 
a viable option for the management of ventricular tachycar-
dia and fibrillation. Prophylactic magnesium administration 
to patients undergoing cardiac surgery seems to reduce the 
incidence and severity of atrial fibrillation, but does not 
affect the incidence of ventricular arrhythmias?O These find-
ings are especially significant considering the low magne-
sium blood levels reported after cardiac surgery .39.41 
Results from our study also show that magnesium was 
associated with less myocardial stunning, which supports 
the findings of Atar et al. 19 and Hertzog et al. 18 The latter 
demonstrated beneficial effects of magnesium on myocar-
dial stunning, albeit in the presence of isoflurane (which 
would have affected their results). Our results showed that 
reversible post-ischaemic regional myocardial dysfunction 
persisted for at least 30 minutes after initiation of reperfu-
sion if no additional magnesium was administered. In con-
trast, the addition of magnesium abolished stunning within 5 
minutes after the onset of reperfusion. 
Diastolic dysfunction also occurs during reperfusion.'2 
Przyklenk et al:3 demonstrated significant diastolic 'stun-
ning' in a dog model after 15 minutes' occlusion of the 
LAD artery. The degree of diastolic dysfunction correlated 
significantly with the recorded systolic stunning, suggesting 
a common mechanism. In our study, diastolic function 
recovered more slowly in the presence of magnesium. This 
is reflected by the PSS, which rapidly returned to normal in 
the control group when reperfusion was started, while the 
magnesium group took longer to recover. In a study in iso-
lated rat hearts, Borchgevrink and colleagues38 demonstrated 
a more rapid recovery of diastolic function when magne-
sium was present during reperfusion, but in the study con-
ducted by Atar et al. 19 the authors recorded an apparently 
higher end-diastolic pressure during reperfusion in the ani-
mals who received magnesium. However, this appareilt dif-
ference was not statistically significant and cannot strictly 
be regarded as support for our findings. 
Data from our experiments also demonstrated a signifi-
cant increase in end-diastolic pressure for the duration of 
reperfusion in animals that received magnesium as opposed 
to those that did not receive magnesium, where the end-
diastolic pressure recovered more rapidly. If the static 
regional end-diastolic compliance is calculated 
(LmaxlL VEDP) and normalised for the initial (control) step, 
the values were 1 for control, 0.43 ± 0.25 (X, SDM) during 
ischaemia and 0.49 ± 0.20, 0.68 ± 0.40 and 0.82 ± 0.70 
mmlmmHg at 5, 30 and 60 minutes' reperfusion respec-
tively. The equivalent values for the magnesium group were 
0.76 ± 0.36, 0.56 ± 0.23, 0.65 ± 0.20 and 0.83 ± 0.79 
mrnImmHg. These values did not differ between groups and 
the difference in LV end-diastolic pressures cannot, there-
fore, be explained by a difference in static end-diastolic 
chamber of muscle compliance. 
The reason(s) for our observation of prolonged diastolic 
dysfunction in the presence of magnesium is not clear. 
Diastolic function is an active process and hence calcium 
homeostasis is involved. Lowering the calcium or admini-
stering an antagonist should decrease the availability of cal-
cium and improve diastolic compliance. Alternatively, mag-
nesium could cause myocardial depression resulting in an 
increased end-diastolic volume. However, as summarised by 
James:3 previous experiments did not demonstrate signifi-
cant depression of myocardial function when magnesium 
was administered in the same dose as used in this study. The 
end-systolic pressure-volume elastance (Ees), which was 
used in this study as an index of myocardial contractility, 
showed a decline in both groups after the initiation of reper-
fusion. However, owing to the large scatter of data and the 
small sample, values did not reach statistical difference 
when compared with control. This numerical decrease in 
con·tractility could be stunning, or a combination of stunning 
and a decrease in function caused by magnesium. However, 
in the final analysis, and irrespective of the exact mecha-
nism, Ees was decreased to a similar degree in both groups 
and therefore cannot explain the difference in L VEDP as 
recorded. Another possible explanation is that the Lo (i.e. 
unstressed LV volume) increased, and if the regional short-
ening was similar to controls, then the Lmax (and indirectly 
the L VEDP) could increase. However, close inspection of 
our data does not support this option as Lo did not change in 
the magnesium group, while it was significantly increased 
in the control group. In addition Lmax did not change, nor 
did it differ between groups. 
The increase in L VEDP after administration of magne-
sium as recorded in this and previ0us experiments will require 
further study. Our methodology and data are insufficient to 
forward a reasonable explanation for this observation. 
These results.do not allow us to be specific with regard to 
the mechanism of the modulating effect on the reperfusion 
injury, or to explain the apparent diastolic dysfunction asso-
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to the known literature, which confirms that reperfusion 
injury is mediated by intracellular calcium overload, and 
that magnesium is a physiological calcium antagonist and 
may also limit the formation of oxygen free radicals.44 The 
clinical ramification of these and the previous findings 
needs to be tested in a randomised fashion, with the magne-
sium administered either before or early during reperfusion. 
We are currently conducting a clinical study in which the 
effect of magnesium on reperfusion arrhythmias and global 
myocardial function is examined in patients undergoing pro-
cedures where aortic cross-clamping is required. In addition, 
data from the MAGIC trial:' which is currently underway, 
will also shed some light on the ability of magnesium, 
when administered early enough, to limit or lessen the 
reperfusion injury (and mortality) in 10 000 high-risk 
myocardial infarct patients. 
This study was supported by the Harry Crossley Foundation. 
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